ClariTrial | Search Clinical Trials

Explore/Arvinas

Status

Phase

26 results for “Arvinas”

Page 1 of 2

Completed

Results posted

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Phase 2Breast Cancer

ARV-471AnastrozoleSurgical resection of breast tumor

Arvinas Inc.152 participants49 sites · United States, Georgia, GermanyCompletes Jul 2024

Compare CT.gov Full analysis →

Active

Results posted

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Phase 3Advanced Breast Cancer

ARV-471Fulvestrant

Pfizer624 participants312 sites · United States, Argentina, AustraliaCompletes Jan 2025

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Phase 1Phase 2KRAS G12D MutationAdvanced Solid Cancer

ARV-806

Arvinas Inc.159 participants14 sites · United StatesCompletes Nov 2027

Compare CT.gov Full analysis →

Completed

A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults

Phase 1Healthy

single dose of vepdegestrant as tablet formulation (Treatment A)single dose of vepdegestrant as tablet formulation (Treatment B)

Pfizer12 participants1 site · BelgiumCompletes Feb 2025

Compare CT.gov Full analysis →

Active

Results posted

A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

Phase 1Breast Neoplasms

vepdegestrant

Pfizer6 participants3 sites · JapanCompletes May 2023

Compare CT.gov Full analysis →

Completed

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Phase 1Healthy

vepdegestrantesomeprazole

Pfizer12 participants1 site · United StatesCompletes May 2024

Compare CT.gov Full analysis →

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Phase 1Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

ARV-393Glofitamab

Arvinas Inc.255 participants17 sites · United States, Canada, DenmarkCompletes Mar 2028

Compare CT.gov Full analysis →

Completed

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Phase 1Phase 2Breast Cancer

ARV-471ARV-471 in combination with palbociclib (IBRANCE®)

Arvinas Estrogen Receptor, Inc.217 participants16 sites · United StatesCompletes Sep 2024

Compare CT.gov Full analysis →

Completed

Results posted

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

Phase 1Healthy

ARV-471Rosuvastatin

Pfizer12 participants1 site · United StatesCompletes Feb 2023

Compare CT.gov Full analysis →

Completed

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

Phase 1Healthy

[phenyl-14C]ARV-471[oxoisoindolin-14C]ARV-471

Pfizer12 participants1 site · United StatesCompletes Jul 2023

Compare CT.gov Full analysis →

Recruiting

A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function

Phase 1Healthy Participants

vepdegestrant

Pfizer24 participants4 sites · United StatesCompletes Dec 2026

Compare CT.gov Full analysis →

Completed

A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults

Phase 1Healthy Participants

Vepdegestrant (Reference)Vepdegestrant (Test)

Pfizer10 participants2 sites · NetherlandsCompletes May 2025

Compare CT.gov Full analysis →

Completed

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

Phase 1Breast Cancer

ARV-471 in combination with Everolimus

Arvinas Estrogen Receptor, Inc.32 participants9 sites · United States, SpainCompletes Jul 2024

Compare CT.gov Full analysis →

Active

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Phase 1Phase 2Breast Cancer

ARV-471Ribociclib

Pfizer20 participants29 sites · United States, Canada, ItalyCompletes Dec 2026

Compare CT.gov Full analysis →

Active

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Phase 1Phase 2Breast Cancer

ARV-471Abemaciclib

Pfizer37 participants39 sites · United States, Canada, ItalyCompletes Sep 2026

Compare CT.gov Full analysis →

1–15 of 26

Explore/Arvinas

Status

Phase

26 results for “Arvinas”

Page 1 of 2

Completed

Results posted

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Phase 2Breast Cancer

ARV-471AnastrozoleSurgical resection of breast tumor

Arvinas Inc.152 participants49 sites · United States, Georgia, GermanyCompletes Jul 2024

Compare CT.gov Full analysis →

Active

Results posted

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Phase 3Advanced Breast Cancer

ARV-471Fulvestrant

Pfizer624 participants312 sites · United States, Argentina, AustraliaCompletes Jan 2025

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Phase 1Phase 2KRAS G12D MutationAdvanced Solid Cancer

ARV-806

Arvinas Inc.159 participants14 sites · United StatesCompletes Nov 2027

Compare CT.gov Full analysis →

Completed

A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults

Phase 1Healthy

single dose of vepdegestrant as tablet formulation (Treatment A)single dose of vepdegestrant as tablet formulation (Treatment B)

Pfizer12 participants1 site · BelgiumCompletes Feb 2025

Compare CT.gov Full analysis →

Active

Results posted

A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

Phase 1Breast Neoplasms

vepdegestrant

Pfizer6 participants3 sites · JapanCompletes May 2023

Compare CT.gov Full analysis →

Completed

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Phase 1Healthy

vepdegestrantesomeprazole

Pfizer12 participants1 site · United StatesCompletes May 2024

Compare CT.gov Full analysis →

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Phase 1Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

ARV-393Glofitamab

Arvinas Inc.255 participants17 sites · United States, Canada, DenmarkCompletes Mar 2028

Compare CT.gov Full analysis →

Completed

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Phase 1Phase 2Breast Cancer

ARV-471ARV-471 in combination with palbociclib (IBRANCE®)

Arvinas Estrogen Receptor, Inc.217 participants16 sites · United StatesCompletes Sep 2024

Compare CT.gov Full analysis →

Completed

Results posted

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

Phase 1Healthy

ARV-471Rosuvastatin

Pfizer12 participants1 site · United StatesCompletes Feb 2023

Compare CT.gov Full analysis →

Completed

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

Phase 1Healthy

[phenyl-14C]ARV-471[oxoisoindolin-14C]ARV-471

Pfizer12 participants1 site · United StatesCompletes Jul 2023

Compare CT.gov Full analysis →

Recruiting

A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function

Phase 1Healthy Participants

vepdegestrant

Pfizer24 participants4 sites · United StatesCompletes Dec 2026

Compare CT.gov Full analysis →

Completed

A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults

Phase 1Healthy Participants

Vepdegestrant (Reference)Vepdegestrant (Test)

Pfizer10 participants2 sites · NetherlandsCompletes May 2025

Compare CT.gov Full analysis →

Completed

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

Phase 1Breast Cancer

ARV-471 in combination with Everolimus

Arvinas Estrogen Receptor, Inc.32 participants9 sites · United States, SpainCompletes Jul 2024

Compare CT.gov Full analysis →

Active

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Phase 1Phase 2Breast Cancer

ARV-471Ribociclib

Pfizer20 participants29 sites · United States, Canada, ItalyCompletes Dec 2026

Compare CT.gov Full analysis →

Active

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Phase 1Phase 2Breast Cancer

ARV-471Abemaciclib

Pfizer37 participants39 sites · United States, Canada, ItalyCompletes Sep 2026

Compare CT.gov Full analysis →

1–15 of 26